rec 15-2739 has been researched along with indoramin in 3 studies
| Studies (rec 15-2739) | Trials (rec 15-2739) | Recent Studies (post-2010) (rec 15-2739) | Studies (indoramin) | Trials (indoramin) | Recent Studies (post-2010) (indoramin) |
|---|---|---|---|---|---|
| 15 | 1 | 1 | 237 | 65 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
| Chang, DJ; Clarke, DE; Daniels, DV; Ford, AP; Gever, JR; Jasper, JR; Lesnick, JD | 1 |
| Pedretti, A; Testa, B; Villa, L; Vistoli, G | 1 |
1 review(s) available for rec 15-2739 and indoramin
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
2 other study(ies) available for rec 15-2739 and indoramin
| Article | Year |
|---|---|
Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Topics: Adrenergic Agents; Animals; CHO Cells; Cloning, Molecular; Cricetinae; Humans; Inositol Phosphates; Radioligand Assay; Receptors, Adrenergic, alpha-1; Recombinant Proteins | 1997 |
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
Topics: Chemical Phenomena; Chemistry, Physical; Ligands; Models, Molecular; Molecular Conformation; Monte Carlo Method; Quantitative Structure-Activity Relationship; Receptors, Adrenergic, alpha-1; Solvents | 2005 |